1 / 1

Pt # 2

Pre-treatment. Post-treatment. II. I. Pt #1. EGFR-del19. EGFR-del19-T790M. (Nuclear β -catenin 21.8%). (51.3 %). III. IV. Pt # 2. EGFR-L858R. EGFR-L858R-T790M. (4.0%). (20.7%). V. VI. Pt # 3. EGFR-del19. EGFR-del19-T790M. (3.8 %). (34.4%). VII. VIII. Pt # 4. EGFR-L858R.

sachi
Télécharger la présentation

Pt # 2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pre-treatment Post-treatment II I Pt #1 EGFR-del19 EGFR-del19-T790M • (Nuclearβ-catenin21.8%) (51.3%) III IV Pt # 2 EGFR-L858R EGFR-L858R-T790M • (4.0%) (20.7%) V VI Pt # 3 EGFR-del19 EGFR-del19-T790M (3.8%) (34.4%) VII VIII Pt # 4 EGFR-L858R EGFR-L858R-T790M (35.0%) (38.9%) Supplementary Figure S2. Expression of β-catenin in pre- and post-EGFR TKIs lung biopsies.

More Related